Zai Lab (NASDAQ:ZLAB) Insider Sells $240,669.84 in Stock

Key Points

• Insider Trading: Zai Lab insider Joshua Smiley sold 6,641 shares at an average price of $36.24, totaling approximately $240,669.84, reducing his ownership in the company by nearly 8%.
• Stock Performance: Zai Lab's stock decreased by 0.7% to $35.44, with a market cap of $3.94 billion and a PE ratio of -17.37.
• Analyst Ratings: The consensus among analysts gives Zai Lab a "Moderate Buy" rating with an average price target of $57.22, despite some recent ratings being downgraded.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Joshua Smiley sold 6,641 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $36.24, for a total transaction of $240,669.84. Following the completion of the sale, the insider directly owned 76,604 shares in the company, valued at approximately $2,776,128.96. This trade represents a 7.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zai Lab Stock Down 0.7%

NASDAQ ZLAB traded down $0.25 on Tuesday, hitting $35.44. 320,371 shares of the stock were exchanged, compared to its average volume of 976,557. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.83 and a fifty-two week high of $44.34. The company has a 50-day moving average price of $36.63 and a 200-day moving average price of $33.64. The company has a market cap of $3.94 billion, a PE ratio of -17.37 and a beta of 1.03.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ZLAB shares. Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a research report on Monday, June 30th. Citigroup reissued a "buy" rating and issued a $69.00 price objective (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $57.22.

Institutional Trading of Zai Lab

Several hedge funds and other institutional investors have recently made changes to their positions in ZLAB. Kingsview Wealth Management LLC grew its position in Zai Lab by 6.0% during the first quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock worth $337,000 after buying an additional 529 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Zai Lab during the 4th quarter worth approximately $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Zai Lab by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock worth $1,496,000 after acquiring an additional 1,200 shares during the period. Walleye Capital LLC increased its stake in Zai Lab by 6.4% in the 1st quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock valued at $805,000 after purchasing an additional 1,338 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Zai Lab by 13.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock worth $453,000 after purchasing an additional 1,483 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.